Abstract Background Since the outbreak of pandemic, severely affected COVID-19 patients receive standard care at intensive unit (ICU), but clinical trials are still ongoing for new expensive treatments. There is a need guiding therapeutic decisions to restrain public healthcare costs and target most efficient therapy. Based on pathophysiology SARS-CoV-2 its ACE2-receptor, angiotensin pathway ac...
